C4 Therapeutics, Inc. (CCCC)
After hours:
| Previous close | 7.54 |
| Open | 7.51 |
| Bid | 7.55 x 1400 |
| Ask | 8.03 x 1100 |
| Day's range | 7.35 - 8.08 |
| 52-week range | 4.84 - 51.21 |
| Volume | |
| Avg. volume | 1,135,496 |
| Market cap | 391.842M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings date | 09 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.64 |
- GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors
WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of CFT8634, an orally bioavailable BiDAC™ degrader targeting BRD9 for the treatment of SMARCB1-perturbed cancers, includin
- Zacks
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C – – Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors – – Potential of TORPEDO® Platform Demonstrated at AACR with Pre-clinical Presentations on CFT7455, CFT8634 and CFT1946 – – Cash, Cash Equivalents and Marketable Securities Total $421.7 million as of
